Newsfeeds Archive - Spark Newswire

3 minute read

June 20, 3:13 AM

MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by

MOR

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

May 27, 4:31 PM

Gainers Sharps Technology (NASDAQ:STSS) stock increased by 87.0% to $0.4 during Monday’s after-market session. The company’s market cap…

ATHE

2 minute read

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

By Vandana Singh

April 29, 12:36 PM

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.

MOR

2 minute read

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

By Vandana Singh

April 23, 3:03 PM

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

INCY

1 minute read

MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share

By Benzinga Newsdesk

April 15, 3:55 PM

On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeover offer (cash offer) to the shareholders of MorphoSys AG, Planegg, Germany ("MorphoSys") for the

MOR

1 minute read

MorphoSys’ Management Board And Supervisory Board Recommend Shareholders Accept Public Takeover Offer By Novartis For €68.00 Per Share In Cash

By Benzinga Newsdesk

April 11, 9:09 AM

Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and

MOR

1 minute read

MorphoSys Spokesperson Says “This Story Is Factually Wrong” In An Emailed Statement To Bloomberg News, In Response To STAT News’ Adam Feuerstein Article Entitled, “Why Novartis Is Going To Walk Away From Its Acquisition”

By Benzinga Newsdesk

February 6, 2:49 PM

Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com) Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or

MOR

2 minute read

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B

By Vandana Singh

February 6, 9:46 AM

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

INCY

4 minute read

MorphoSys Enters Into Business Combination Agreement To Be Acquired By Novartis For €2.7 Billion Equity Value; €68/Share In cash

By Benzinga Newsdesk

February 5, 5:53 PM

https://www.eqs-news.com/company/morphosys-ag/news/5b719341-ea7c-11e8-902f-2c44fd856d8cMorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value Tafasitamab sold

MOR

4 minute read

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor

February 5, 1:56 PM

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

$SRM

Latest news

Novartis to Squeeze Out MorphoSys Minority Shareholders, Initiate Delisting

12 Health Care Stocks Moving In Monday’s After-Market Session

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share

MorphoSys’ Management Board And Supervisory Board Recommend Shareholders Accept Public Takeover Offer By Novartis For €68.00 Per Share In Cash

MorphoSys Spokesperson Says “This Story Is Factually Wrong” In An Emailed Statement To Bloomberg News, In Response To STAT News’ Adam Feuerstein Article Entitled, “Why Novartis Is Going To Walk Away From Its Acquisition”

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B

MorphoSys Enters Into Business Combination Agreement To Be Acquired By Novartis For €2.7 Billion Equity Value; €68/Share In cash

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday’s Mid-Day Session